European Journal Of Cancer

European Journal Of Cancer

欧洲癌症杂志

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《European Journal Of Cancer》是由Elsevier Ltd出版社于1990年创办的英文国际期刊(ISSN: 0959-8049,E-ISSN: 1879-0852),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为肿瘤学-医学。作为SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA开放获取模式(OA占比0.2544...%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比90.25%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在318篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

European Journal Of Cancer审稿周期约为 约1.0个月 约5.3周。该刊近年未被列入国际预警名单,年发文量约318篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 318 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
2区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
2区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 38 / 322

88.4%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 34 / 322

89.6%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:11.5 SJR:2.501 SNIP:1.994
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q1 47 / 404

88%

大类:Medicine 小类:Cancer Research Q1 40 / 230

82%

期刊发文

  • KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer

    Author: Xu, Jianming; Ying, Jieer; Liu, Rongrui; Wu, Jun; Ye, Feng; Xu, Nong; Zhang, Yanqiao; Zhao, Rusen; Xiang, Xiaojun; Wang, Jianhong; Lin, Xiaoyan; Xu, Huiting; Gao, Shegan; Luo, Suxia; Guo, Baohong; Li, Xionghui; Su, Yangzhi; Wang, Qian

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 1-12. DOI: 10.1016/j.ejca.2022.10.004

  • Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer

    Author: Swain, Sandra M.; Tan, Antoinette R.; Gianni, Luca; Kuemmel, Sherko; Dang, Chau T.; Schneeweiss, Andreas; O'Shaughnessy, Joyce; Liu, Haiying; Aguila, Christian; Heeson, Sarah; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora; Loibl, Sibylle

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 70-81. DOI: 10.1016/j.ejca.2022.09.024

  • Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)

    Author: Sheng, Xinan; Ye, DingWei; Zhou, Aiping; Yao, Xin; Luo, Hong; He, Zhisong; Wang, Zengjun; Zhao, Yingchao; Ji, Zhigang; Zou, Qing; He, Chaohong; Guo, Jianming; Tu, Xinhua; Liu, Ziling; Shi, Benkang; Liu, Ben; Chen, Peng; Wei, Qiang; Hu, Zhiquan; Zhang, Yanqiao; Jiang, Kui; Zhou, Fangjian; Wu, Dapeng; Fu, Cheng; Li, Xingya; Wu, Bin; Wang, Lijie; Qin, Shukui; Li, Gang; Liu, Yunpeng; Guo, Hongqian; Chen, Kehe; Zhang, Dahong; Wang, Gongxian; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Guo, Jun

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 205-215. DOI: 10.1016/j.ejca.2022.10.025

  • Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases

    Author: Guo, Ye; Zhang, Weijie; Ying, Jieer; Zhang, Yanqiao; Pan, Yueyin; Qiu, Wensheng; Fan, Qingxia; Xu, Qi; Ma, Yue; Wang, Gang; Guo, Jing; Su, Weiguo; Fan, Songhua; Tan, Panfeng; Wang, Yan; Luo, Yang; Zhou, Hui; Li, Jin

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 181, Issue , pp. 26-37. DOI: 10.1016/j.ejca.2022.12.004

  • Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    Author: Cueva, Juan F.; Palacio, Isabel; Churruca, Cristina; Herrero, Ana; Pardo, Beatriz; Constenla, Manuel; Santaballa, Ana; Manso, Luis; Estevez, Purificacin; Maximiano, Constanza; Legeren, Marta; Marquina, Gloria; de Juan, Ana; Quindos, Maria; Sanchez, Luisa; Barquin, Arantzazu; Fernandez, Isaura; Martin, Cristina; Juarez, Asuncin; Martin, Teresa; Garcia, Yolanda; Yubero, Alfonso; Gallego, Alejandro; Bueno, Alejandro Martinez; Guerra, Eva; Gonzalez-Martin, Antonio

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 3-14. DOI: 10.1016/j.ejca.2022.12.023

  • Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial

    Author: Wang, Xuan; Wu, Xiaowen; Yang, Yue; Xu, Weiran; Tian, Hui; Lian, Bin; Chi, Zhihong; Si, Lu; Sheng, Xinan; Kong, Yan; Zhou, Li; Mao, Lili; Li, Siming; Tang, Bixia; Yan, Xieqiao; Bai, Xue; Guo, Jun; Cui, ChuanLiang

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 57-65. DOI: 10.1016/j.ejca.2022.12.027

  • First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

    Author: Reck, Martin; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Cheng, Ying; Sakai, Hiroshi; Paz-Ares, Luis; Lu, Shun; John, Thomas; Sun, Xiaowu; Moisei, Aniela; Taylor, Fiona; Lawrance, Rachael; Zhang, Xiaoqing; Sylvester, Judi; Yuan, Yong; Blum, Steven I.; Penrod, John R.; Carbone, David P.

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 183, Issue , pp. 174-187. DOI: 10.1016/j.ejca.2023.01.015

  • OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Author: Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco

    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 184, Issue , pp. 39-47. DOI: 10.1016/j.ejca.2023.01.031